A

Quest Diagnostics (DGX) reported Q3 2026 adjusted earnings of $3.00 per share (up 15.4% YoY) and revenues of $3.10 billion (up 10% YoY), both beating consensus estimates. The company raised full-year 2026 revenue guidance to $12.065-$12.105 billion and adjusted EPS outlook to $11.25-$11.35.

Despite strong results, DGX shares fell 1.6% in pre-market trading. Operating margins improved 40 basis points to 16.7%, driven by strong testing demand and organic requisition volume growth of 14.4%.

The First Trust Water ETF (FIW) is a passively managed fund with $1.71 billion in assets that tracks the ISE Clean Edge Water Index. It has a 0.5% expense ratio and 0.76% dividend yield.

The fund has declined 3.23% year-to-date and 7.75% over the past year, with a beta of 0.99 indicating medium risk. It carries a Zacks ETF Rank of 3 (Hold) and is compared to alternative water ETFs like CGW and PHO.

The global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions.

The global oligonucleotide synthesis reagents market is valued at USD 723.3 million in 2025 and is projected to reach USD 1.75 billion by 2033, growing at a 11.9% CAGR. Growth is driven by increasing demand for nucleic acid-based therapeutics including siRNA, antisense oligonucleotides, CRISPR gene editing, and mRNA platforms across oncology, rare genetic disorders, and infectious diseases.

The global magnetic beads market is projected to grow from USD 3.90 billion in 2026 to USD 6.18 billion by 2032, driven by automation, molecular diagnostics, genomics, and bioprocessing applications. Key growth drivers include adoption of automated magnetic separation platforms, advanced surface chemistries, AI-enabled workflow optimization, and expanding diagnostics capacity across regions. Strategic priorities for industry leaders include developing application-specific chemistries, strengthening supply-chain resilience, and leveraging AI analytics.

Medtronic reported strong Q1 fiscal 2027 results with adjusted EPS of $1.45 (up 15.1% YoY) and revenues of $9.76 billion (up 13.7% YoY), both beating consensus estimates. The company raised full-year organic revenue growth guidance to 7.25%-7.75% and adjusted EPS guidance to $5.94-$6.00.

However, shares have declined 6.4% since the earnings report, underperforming the S&P 500. Analyst estimates have trended downward post-earnings, and the stock carries a Zacks Rank #3 (Hold) rating.